For Q1 FY2026 ended March 31, 2026, Madrigal Pharmaceuticals reported revenue of $311.3 million, up 126.8% year-over-year. Net loss was $94.4 million, a 28.9% improvement from the prior year. Operating loss was $92.7 million, improving 16.9% year-over-year. Diluted EPS was -$3.25, compared to -$4.31 in the prior year.
•Revenue surged 126.8% YoY to $311.3 million.
•Net loss narrowed 28.9% YoY to $94.4 million.
•Operating loss improved 16.9% YoY to $92.7 million.
•Diluted EPS improved to -$3.25 from -$4.31.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. Founded in 2016, the company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. Its primary product is Rezdiffra, a liver-directed thyroid hormone receptor beta agonist specifically designed to treat MASH. The company operates in the biotechnology industry within the healthcare sector, concentrating on addressing the significant unmet medical need in MASH, a progressive liver disease. Madrigal's research and development efforts are centered on advancing this therapeutic option, which targets key pathways involved in liver fibrosis and inflammation associated with MASH.
Where is Madrigal Pharmaceuticals (MDGL) listed and in what currency?
Madrigal Pharmaceuticals is publicly traded on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol MDGL. Its shares are denominated in US Dollars (USD), reflecting its primary listing in the United States. The company's stock is part of the US equity market, and investors can trade MDGL shares on the Nasdaq exchange during regular market hours. As a US-based company, its financial reporting and stock pricing are conducted in USD, making it accessible to both domestic and international investors through brokerage platforms that support Nasdaq listings.
What sector and industry does Madrigal Pharmaceuticals (MDGL) belong to?
Madrigal Pharmaceuticals operates within the healthcare sector, specifically in the biotechnology industry. As a biotechnology company, it engages in the research, development, and commercialization of innovative therapies for serious diseases. Its focus on metabolic dysfunction-associated steatohepatitis (MASH) places it at the intersection of liver disease and metabolic disorders. The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and the potential for breakthrough treatments. Madrigal's work in this field involves leveraging scientific expertise to create targeted therapies, such as its lead product Rezdiffra, which addresses a significant area of unmet medical need.
Where is Madrigal Pharmaceuticals (MDGL) headquartered and what markets does it serve?
Madrigal Pharmaceuticals is headquartered in West Conshohocken, Pennsylvania, United States. The company primarily serves the US market, as indicated by its focus on delivering therapeutics for MASH in the United States. Its operations are centered in the US, where it conducts research, development, and commercialization activities. While the company's current efforts are domestic, its therapies may have potential for global expansion in the future. The headquarters location in Pennsylvania places it within a key biopharmaceutical hub on the East Coast, providing access to talent, research institutions, and strategic partners.
How does Madrigal Pharmaceuticals (MDGL) make money?
Madrigal Pharmaceuticals generates revenue primarily through the commercialization of its approved product, Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). As a biopharmaceutical company, its business model involves developing novel therapeutics, obtaining regulatory approval, and then marketing and selling these drugs to healthcare providers and patients. Revenue is derived from product sales, and the company may also pursue licensing agreements or partnerships to expand its reach. Since its founding in 2016, Madrigal has focused on building a pipeline around MASH, with Rezdiffra being its first commercial product. The company's financial performance depends on market adoption, pricing, reimbursement, and ongoing research investments.